Evidence map›Paper›PMID 24642735›Full record

ArticleClinical pharmacology and therapeutics2014

Evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity.

C Lanvers-Kaminsky, I Malath, D Deuster, G Ciarimboli, J Boos, A G Am Zehnhoff-Dinnesen

Abstract readLetterComment
PubMed Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Platinum-induced hearing loss after treatment for childhood cancer.The Cochrane database of systematic reviews · 2016
    Pooled it
  3. Agonists and Inhibitors of the cGAS-STING Pathway.Molecules (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

C Lanvers-KaminskyDepartment of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany.
I MalathDepartment of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany.
D DeusterDepartment of Phoniatrics and Pedaudiology, University Hospital of Muenster, Muenster, Germany.
G Ciarimboli1] Experimental Nephrology, Department of Internal Medicine D, University Hospital of Muenster, Muenster, Germany [2] Interdisciplinary Center for Clinical Research, University Hospital of Muenster, Muenster, Germany.
J BoosDepartment of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany.
A G Am Zehnhoff-Dinnesen1] Department of Phoniatrics and Pedaudiology, University Hospital of Muenster, Muenster, Germany [2] Interdisciplinary Center for Clinical Research, University Hospital of Muenster, Muenster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AnimalsAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCatechol O-MethyltransferaseCisplatinFemaleHearing LossHumansMaleMethyltransferasesAntineoplastic AgentsATP-Binding Cassette, Sub-Family C ProteinsCatechol O-MethyltransferaseCisplatinMethyltransferases

Identifiers

PMID24642735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.